PositoAI/ US/ Cue Biopharma, Inc.

Cue Biopharma, Inc.

NasdaqCM: CUE · Healthcare

Positivity Index

#6,312 / 6,774

Global

#3,603 / 4,000

United States

Positivity Score

-8,509

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Cue Biopharma, Inc. — Overview & Financial Snapshot

Cue Biopharma, Inc. (NasdaqCM: CUE) is a Healthcare company, ranked #6,312 of 6,774 companies globally and #3,603 of 4,000 in United States on PositoAI, with a Positivity Score of -8,509. Its market capitalisation is ₹1,295.28 Cr ($137.22M), P/E ratio is -0.6 and P/B ratio is 59.40. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

P/B Ratio 59.40

P/E Ratio -0.6

D/E Ratio 1.33

ROE -1603.48%

Owes vs Owns ? 0.92× High $0.92 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-2,793.02$-29.59

Forward EPS ₹-45.31$-0.48

Beta 2.63

Market Cap ₹1,295.28 Cr$137.22M

What these numbers mean →

What does Cue Biopharma, Inc. do?

What is Cue Biopharma, Inc.'s P/E and P/B ratio?

Cue Biopharma, Inc. has a P/E ratio of -0.6 and a P/B ratio of 59.40.

What is Cue Biopharma, Inc.'s debt-to-equity ratio?

Cue Biopharma, Inc. has a debt-to-equity ratio of 1.33.

How much does Cue Biopharma, Inc. owe compared with what it owns?

Cue Biopharma, Inc. owes $0.92 for every $1 it owns (balance sheet Jun 2026), which is high.

What is Cue Biopharma, Inc.'s Positivity rank?

Cue Biopharma, Inc. is ranked #6,312 of 6,774 companies globally and #3,603 of 4,000 in United States on PositoAI, with a Positivity Score of -8,509.

Does Cue Biopharma, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Cue Biopharma, Inc..

Where can I read the latest news about Cue Biopharma, Inc.?

Recent headlines about Cue Biopharma, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Cue Biopharma, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Cue Biopharma, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.